好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Decline in Walking Capacity (WC) in Ambulatory Amyotrophic Lateral Sclerosis Patients (ambALS) Is Not Accompanied by Decline in Walking Distance (WD) and Walking Velocity (WV) Recorded at 2 Minutes Intervals during the 6 Minutes Walk Test (6MWT)
Anterior Horn
P07 - (-)
087
BACKGROUND: The 6MWT is being increasingly used in a variety of neurodegenerative motor system diseases including ambALS (Arch Phys Med Rehabil 2010; 91(12):1920-1929). The 6MWT was validated with other outcome measures (OM) used to evaluate ambALS (Neurology; 2012; 76 (Suppl 1), PO1.107: 113. It is not known, however, if fatigue during the 6MWT would compromise validity and usefulness in ambALS.
DESIGN/METHODS: fatigue signs were evaluated by patients inability to sustain a constant level of performance in WD and velocity WV measured in 2 minutes intervals (0-2, 2-4, 4-6) during standardized 6MWT in 31 AALS patients (20/12 M/F, age = 64卤10) using their usual assistive devices if needed. Change in heart rate (HR) was determined from the ratio between post 6MWT HR and maximum predicted HR (= 220 - age) and change in arterial blood oxygen saturation (SaO2).
RESULTS: WC was 361卤107 meter [compared with 374卤17 in patients with left ventricular dysfunction, J.A.M.A.1993; 270:1702, and 631卤93 in healthy elderly aged 50卤85 yrs, Eur Respir J 1999; 14:270]. No change in WD [Mean 卤 SD] recorded at 2, 4, and 6 minutes [125卤3, 116卤4, and 120卤4 meter respectively] or in corresponding WV [1.04卤0.27, 0.97卤0.32, and 1.00卤0.35 m/sec], (ANOVA p=0.65)]. Pre to post 6MWT increase in HR was 20卤8 bpm reflecting moderate exercise intensity of 63卤10%. There was no change from pre to post 6MWT SaO2 (97卤2 to 96卤2).
CONCLUSIONS: The 6MWT as submaximal functional capacity test in ambALS is not limited by FS. The decline in walking capacity in ambALS is most likely related to weakness, postural instability, and/or change in gait pattern due to central and peripheral factors. Other clinimetrics properties of the 6MWT in ambALS, such as it reliability and sensitivity need to be established.
Authors/Disclosures
Mohammed S. Sanjak, PhD (Carolinas Healthcare System)
PRESENTER 		No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Urvi G. Desai, MD, FAAN (Dept of Neurology, CMC) Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Takeda. Dr. Desai has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Fulcrum. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Desai has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Argenx.
Edward Fox, MD, PhD, FAAN Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for GW Pharmaceuticals. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alexion. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. The institution of Dr. Fox has received research support from Biogen. The institution of Dr. Fox has received research support from Genentech. The institution of Dr. Fox has received research support from Celgene - BMS. The institution of Dr. Fox has received research support from Chugai. The institution of Dr. Fox has received research support from Novartis. The institution of Dr. Fox has received research support from EMD-Serono. The institution of Dr. Fox has received research support from TG Therapeutics. The institution of Dr. Fox has received research support from AbbVie. The institution of Dr. Fox has received research support from Sanofi Genzyme. The institution of Dr. Fox has received research support from AbbVie.
No disclosure on file
No disclosure on file
Elena Bravver, MD No disclosure on file
Benjamin R. Brooks, MD, FAAN (Clinical Trials Planning LLC) Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Mitsubishi Tanabe Pharma America. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Medicinova. Dr. Brooks has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ionis. Dr. Brooks has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Mitsubishi Tanabe Pharma America. The institution of Dr. Brooks has received research support from Mitsubishi TanabePharma America. Dr. Brooks has received personal compensation in the range of $0-$499 for serving as a Member Annual Surveillance Committee CDC National ALS Registry with Center for Disease Control Agency Toxic Substances Disease Registry. Dr. Brooks has a non-compensated relationship as a Member ALS Quality Measures Subcommittee with 好色先生 that is relevant to AAN interests or activities.